Skip to main content
Xiangxue Pharmaceutical Co., Ltd. logo

Xiangxue Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300147 ISIN · CNE100000Y92 LEI · 3003000D8UMO4KQ95B57 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,287 across all filing types
Latest filing 2023-08-02 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300147

About Xiangxue Pharmaceutical Co., Ltd.

https://www.xphcn.com

Xiangxue Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of modern Traditional Chinese Medicine (TCM), chemical drugs, and biological products. The company is recognized for its focus on the modernization of TCM, utilizing advanced technology to standardize and enhance traditional formulas. Its flagship products include anti-viral oral liquids and Banlan'gen granules, which are widely used for respiratory health. Beyond traditional treatments, the company has expanded into high-tech biomedical fields, including precision medicine and adoptive cell therapy, specifically TCR-T cell technology for cancer treatment. Xiangxue operates a comprehensive value chain encompassing medicinal herb cultivation, pharmaceutical manufacturing, and healthcare services. By integrating digital technology with pharmaceutical expertise, the company aims to provide integrated health solutions and innovative therapies.

Recent filings

Filing Released Lang Actions
2023年度向特定对象发行股票方案论证分析报告
Capital/Financing Update Classification · 95% confidence The document is titled "2023年度向特定对象发行股票方案论证分析报告" which translates to "2023 Annual Report on the Proposal and Analysis of Directed Stock Issuance to Specific Objects." It details a plan for a directed issuance of A-shares to specific investors, including the background, purpose, legal compliance, pricing, and impact on financial indicators. The content focuses on a capital raising activity through stock issuance to specific investors, discussing the use of proceeds, regulatory compliance, pricing methodology, and shareholder impact. This is a detailed report on a capital/financing activity rather than a general annual report or earnings release. It is not a simple announcement or a proxy statement but a comprehensive analysis report related to a capital raising event. Therefore, the document fits best under the category "Capital/Financing Update (CAP)" which covers updates on company fundraising and financing activities.
2023-08-02 Chinese
2023年度向特定对象发行股票募集资金投资项目可行性分析报告
Capital/Financing Update Classification · 95% confidence The document is titled "2023 年度向特定对象发行股票募集资金投资项目可行性分析报告" which translates to "2023 Feasibility Analysis Report on Fundraising Investment Projects by Private Placement of Shares." It details the company's plan to raise funds through a specific stock issuance, describing the use of proceeds, investment projects, their necessity, feasibility, and impact on the company. The content focuses on capital raising and investment projects funded by the issuance. There are no financial statements or quarterly/yearly financial results presented, nor is it an announcement of a report publication. The document is a detailed feasibility analysis related to capital raising and investment projects. Therefore, it fits best under the category "Capital/Financing Update (CAP)" which covers updates on company fundraising and financing activities.
2023-08-02 Chinese
关于最近五年被证券监管部门和交易所采取监管措施或处罚情况的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding regulatory and disciplinary actions taken against the company by securities regulatory authorities and stock exchanges over the past five years. It includes descriptions of violations, penalties, and the company's corrective measures. The content focuses on regulatory compliance issues, penalties, and remediation rather than presenting financial statements or audit opinions. It is not a full annual report, audit report, earnings release, or other financial report. The document is a regulatory disclosure about past regulatory measures and penalties, which fits the category of Regulatory Filings (RNS).
2023-08-02 Chinese
关于无需编制前次募集资金使用情况专项报告的说明公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the exemption from preparing a special report on the use of previously raised funds. It references regulatory guidelines from the China Securities Regulatory Commission and details about past fundraising activities, confirming that the previous fundraising occurred more than five accounting years ago, thus no new report is required. The document is short (832 characters) and serves as a regulatory compliance announcement rather than a detailed financial report or audit. It does not contain financial statements or detailed financial data but rather a compliance explanation and regulatory reference. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-08-02 Chinese
监事会关于公司向特定对象发行股票事项的书面审核意见
Capital/Financing Update Classification · 95% confidence The document is a written supervisory board opinion regarding the company's issuance of shares to specific investors. It references compliance with various laws and regulations related to stock issuance, discusses the issuance plan, pricing, feasibility reports, and shareholder interests. The document is not the issuance plan itself but an official opinion or review related to the issuance. It does not contain financial statements or detailed financial data but rather a regulatory compliance and supervisory review. This fits best under Capital/Financing Update (CAP) as it relates to company fundraising activities and capital structure changes.
2023-08-02 Chinese
独立董事关于第九届董事会第十三次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal opinion statement from independent directors regarding various matters to be discussed at the 13th meeting of the 9th board of directors of Guangzhou Xiangxue Pharmaceutical Co., Ltd. It includes pre-approval opinions on related party transactions, conditions and plans for a specific stock issuance, feasibility analysis reports, dilution and compensation measures, dividend planning, and authorization for the board to handle issuance matters. The document references compliance with company law, securities law, and regulatory guidelines, and is clearly a governance-related document focused on board-level approvals and opinions rather than financial results or report publication. It does not contain financial statements or earnings data, nor is it a report publication announcement. The content aligns with board/management information about corporate governance and board meeting matters, especially related to capital raising and shareholder interests. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is under 5,000 characters, but it is not merely an announcement of a report; it contains substantive board opinions and approvals.
2023-08-02 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.